The hypercoagulable state in cancer patients

Falanga, Anna; Ofosu, Frederick A.; Delaini, Federica; Oldani, Elena; Dewar, Lori; L, Lui; Barbui, Tiziano

doi:10.1097/00001721-199401000-00004

Cited by 40 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment of cancer inoculated groups with glutathione significantly (P < 0.05) reduced this elevation in platelet counts than inoculated non treated mice [60]. Present results are logic where previous literature confirmed the close association between cancer progression and platelets activation that was pivotal for cancer progression and activation [61] [62].…”

Section: Hematological Studysupporting

confidence: 83%

How to Return the Death Programs of Cancer Cells to Work again and Cure Cancer within a Short Time?

El-Khodary¹,

Hasan²,

Hassan³

et al. 2019

CellBio

View full text Add to dashboard Cite

Cancer is cell fleeing from death by blocking the intrinsic and extrinsic pathways of cell death programs. In the present work, the experimental formula was designed to remove these blockers. It was applied on 120 Swiss albino mice which were inoculated intraperitoneally and subcutaneously with Ehrlich Ascites Carcinoma cells; 1 × (10⁶) cell/mouse. The activity of the cell death programs of the tumor was detected by measuring the volume of Ascites fluid, counting the number of dead cancer cells, measuring the size of the tumor, detecting the positive reaction of caspase enzyme in cancer cells and presence of macrophages and apoptotic bodies in tumor tissue. The experimental formula succeeded in removing the blockers of the cell death program in cancer cells returning the cell death program to work again.

show abstract

Section: Hematological Studysupporting

confidence: 83%

How to Return the Death Programs of Cancer Cells to Work again and Cure Cancer within a Short Time?

El-Khodary¹,

Hasan²,

Hassan³

et al. 2019

CellBio

View full text Add to dashboard Cite

show abstract

“… 10 , 11 Other mechanisms such as neutrophil extracellular traps, procoagulant tumor proteins, chemotherapy, and changes in coagulation factor and plasminogen activator inhibitor 1 (PAI-1) have been associated with increased risk of thrombosis. 12 , 13 , 14 , 15 , 16 In a study by Lisman et al investigating the association between clot lysis time (measured by a dynamic clot formation and lysis assay) and deep-vein thrombosis (DVT), the authors found that patients with clot lysis times above the 90th percentile for healthy controls had an odds ratio of 2 for DVT. 17 Bleeding, however, is largely attributed to thrombocytopenia in patients with hematological cancer, with the exception of acute promyelocytic leukemia (APL) in which disseminated intravascular coagulation and hyperfibrinolysis plays a major role.…”

Section: Introductionmentioning

confidence: 99%

Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma

Bønløkke,

Fenger-Eriksen,

Ommen

et al. 2023

Blood Advances

View full text Add to dashboard Cite

Thrombosis and bleeding are significant contributors to morbidity and mortality in patients with hematological cancer, and the impact of altered fibrinolysis on bleeding and thrombosis risk is poorly understood. In this prospective cohort study, we investigated the dynamics of fibrinolysis in hematological cancer patients. Fibrinolysis was investigated prior to treatment and three months after treatment initiation. A dynamic clot formation and lysis assay was performed beyond the measurement of plasminogen activator inhibitor 1, tissue- and urokinase-type plasminogen activators (tPA and uPA), plasmin-antiplasmin complexes (PAP), α-2-antiplasmin activity, and plasminogen activity. Clot initiation, clot propagation, and clot strength were assessed using thromboelastometry (ROTEM®). A total of 79 patients were enrolled. Lymphoma patients displayed impaired fibrinolysis with prolonged 50% clot lysis time compared to healthy controls (p = 0.048). They also displayed decreased clot strength at follow-up compared to at diagnosisp (p = 0.001). A patient with amyloid-light-chain amyloidosis having overt bleeding at diagnosis displayed hyperfibrinolysis, indicated by a reduced 50% clot lysis time, α-2-antiplasmin activity, and plasminogen activity and elevated tPA and uPA. A patient with acute promyelocytic leukemia also displayed marked hyperfibrinolysis with very high PAP indicating extreme plasmin generation, and clot formation was not measurable probably due to the extremely fast fibrinolysis. Fibrinolysis returned to normal after treatment in both patients. In conclusion, lymphoma patients showed signs of impaired fibrinolysis and increased clot strength, whereas hyperfibrinolysis was seen in patients with acute promyelocytic leukemia and light-chain amyloidosis. Thus, investigating fibrinolysis in hematological cancer patients could have diagnostic value.

show abstract

High incidence of thromboembolism in patients with central nervous system lymphoma

Goldschmidt

Linetsky²,

Shalom³

et al. 2003

Cancer

View full text Add to dashboard Cite

Polymorphism, in which there exist different crystal forms for the same chemical compound, is an important phenomenon in pharmaceutical manufacturing. In this article, a kinetic model for the crystallization of L‐glutamic acid polymorphs is developed from experimental data. This model appears to be the first to include all of the transformation kinetic parameters including dependence on the temperature. The kinetic parameters are estimated by Bayesian inference from batch data collected from two in situ measurements: ATR‐FTIR spectroscopy is used to infer the solute concentration, and FBRM that provides crystal size information. Probability distributions of the estimated parameters in addition to their point estimates are obtained by Markov Chain Monte Carlo simulation. The kinetic model can be used to better understand the effects of operating conditions on crystal quality, and the probability distributions can be used to assess the accuracy of model predictions and incorporated into robust control strategies for polymorphic crystallization. © 2008 American Institute of Chemical Engineers AIChE J, 2008

show abstract

The hypercoagulable state in cancer patients

Cited by 40 publications

References 0 publications

How to Return the Death Programs of Cancer Cells to Work again and Cure Cancer within a Short Time?

How to Return the Death Programs of Cancer Cells to Work again and Cure Cancer within a Short Time?

Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma

High incidence of thromboembolism in patients with central nervous system lymphoma

Contact Info

Product

Resources

About